Compare AbCellera Biologics Inc (ABCL) vs GoPro Inc (GPRO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs GoPro Inc — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while GoPro Inc trades at $0.72 (market cap $121.79M). The key difference: AbCellera Biologics Inc is far larger — about 19.3× GoPro Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | GPRO | |
|---|---|---|
Market Cap | $2.35B | $121.79M |
Sector | Health | Technology |
52-Week High | $8.12 | $2.88 |
52-Week Low | $2.78 | $0.64 |
Enterprise Value | $1.99B | $169.74M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
GoPro (GPRO) trades at $0.701, down 3.96% for the day, reflecting persistent financial distress. The stock shows a bearish technical outlook with negative cash flows and consecutive earnings misses. Recent news highlights a strategic review for potential sale or merger, announced on May 11, 2026, following weak Q1 2026 results. Revenue has declined from $1.1B in 2022 to $652M in 2025, with net losses deepening, indicating significant operational challenges.
The investment outlook remains highly speculative. The strategic sale process offers a potential catalyst, but substantial risks include ongoing cash burn, negative equity, and competitive pressures. Analyst sentiment is mixed with a cautious hold bias. Investors should weigh the binary outcome of a successful strategic transaction against the company's fundamental deterioration and explicit going-concern risks noted in recent disclosures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
